*Amanat: Corxel's Lead Pdt Candidate, CX11, Is an Investigational, Once-Daily, Oral Small-Molecule GLP-1 RA Being Developed for Obesity, Type 2 Diabetes, Related Cardiometabolic Conditions >AMAN

Dow Jones · 2d ago

Please log in to view news